Global Blood Therapeutics (United States)

Recent papers from Global Blood Therapeutics (United States)

1. Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and PatientsClinical Pharmacology & Therapeutics · 2025
2. Discovery of Osivelotor (GBT021601): A Potent, Next-Generation Sickle Hemoglobin Polymerization InhibitorACS Medicinal Chemistry Letters · 2025
3. A community effort to optimize sequence-based deep learning models of gene regulationNature Biotechnology · 2024
4. Assessing multilevel barriers to hydroxyurea adherence in youth with sickle cell disease using pharmacy‐based refill recordsPediatric Blood & Cancer · 2024
5. Building Sustainable Funding for Teacher Residency ProgramsJournal of Education Human Resources · 2024
6. Concentration of voxelotor in sickle cell disease can be estimated using electrophoresis and high-performance liquid chromatographyAmerican Journal of Clinical Pathology · 2024
7. Cognition and education benefits of increased hemoglobin and blood oxygenation in children with sickle cell diseasePLoS ONE · 2023
8. Relationship between hemoglobin, hemolysis, and transcranial Doppler velocities in children with sickle cell disease: Results from a long‐term natural history study in Italy in the era of multimodal therapyEuropean Journal Of Haematology · 2023
9. Editorial: Stress erythropoiesisFrontiers in Physiology · 2023
10. Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transportersClinical and Translational Science · 2023
11. Hemoglobin and End-Organ Damage in Individuals with Sickle Cell DiseaseCurrent Therapeutic Research · 2023
12. Patient‐Reported Experiences in Voxelotor‐Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview StudyBioMed Research International · 2023
13. Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese ParticipantsClinical Pharmacology in Drug Development · 2022
14. Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood TherapeuticsExpert Opinion on Biological Therapy · 2022
15. Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease centerPediatric Blood & Cancer · 2022
16. Synthesis and Evaluation of Simplified Cruentaren A AnaloguesThe Journal of Organic Chemistry · 2022
17. Consensus definition of essential, optimal, and suggested components of a pediatric Sickle Cell Disease Center2022
18. Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) EvaluationJournal of Medicinal Chemistry · 2022
19. P1486: Trials in Progress: The Thrive Studies Evaluating the Efficacy, Safety, and Long-Term Treatment With Inclacumab, a P-Selectin Inhibitor, in Patients With Sickle Cell DiseaseHemaSphere · 2022
20. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 yearsPediatric Blood & Cancer · 2022